Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
| Episode | Date |
|---|---|
|
First-trimester doxycycline tied to more pregnancy loss
|
Nov 14, 2026 |
|
Oral povorcitinib: 75% facial repigmentation in ~19% vs 3-7%
|
Nov 07, 2026 |
|
Ruxolitinib cream for paediatric AD: no new safety signals
|
Oct 31, 2026 |
|
HS guideline strongly backs four biologics and pain checks
|
Oct 24, 2026 |
|
Lichen planus tied to higher oral and vulvar cancer rates
|
Oct 17, 2026 |
|
CLIPI score predicts PFS in advanced MF/Sézary beyond stage
|
Oct 10, 2026 |
|
Sonelokimab in HS: HiSCR75 43% vs 15%, no new safety signals
|
Oct 03, 2026 |
|
Ruxolitinib cream improves lichen planus, no serious AEs
|
Sep 26, 2026 |
|
IL-17 inhibitors for psoriasis tied to 2-4x candidiasis risk
|
Sep 19, 2026 |
|
Mohs in cSCC: smaller defects, no significant recurrence gap
|
Sep 12, 2026 |
|
Recibokibart: GPP pustules clear/near-clear in ~86% vs 9%
|
Sep 05, 2026 |
|
Brepocitinib tied to better dermatomyositis skin and itch
|
Aug 29, 2026 |
|
HS: nearly 4 in 10 Hurley I report very severe QoL loss
|
Aug 22, 2026 |
|
Upadacitinib repigments ~1 in 5 with vitiligo vs 6% placebo
|
Aug 15, 2026 |
|
Weekly adalimumab most cost-efficient for HS in 5 countries
|
Aug 08, 2026 |
|
This Week in Dermatology — Jul 31, 2026
|
Aug 01, 2026 |
|
This Week in Dermatology — Jul 24, 2026
|
Jul 25, 2026 |
|
This Week in Dermatology — Jul 17, 2026
|
Jul 18, 2026 |
|
This Week in Dermatology — Jul 10, 2026
|
Jul 11, 2026 |
|
This Week in Dermatology — Jul 3, 2026
|
Jul 04, 2026 |
|
This Week in Dermatology — Jun 27, 2026
|
Jun 27, 2026 |
|
This Week in Dermatology — Jun 20, 2026
|
Jun 20, 2026 |
|
This Week in Dermatology — Jun 13, 2026
|
Jun 13, 2026 |
|
This Week in Dermatology — Jun 6, 2026
|
Jun 06, 2026 |
|
This Week in Dermatology — May 29, 2026
|
May 30, 2026 |
|
This Week in Dermatology — May 21, 2026
|
May 21, 2026 |
|
This Week in Dermatology — May 14, 2026
|
May 14, 2026 |